Hornray Pharmasea Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 6 Year, 14 Days
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -16.48%
- Ebitda 51.02%
- Net Worth -118.70%
- Total Assets -37.56%
About Hornray Pharmasea
Hornray Pharmasea Private Limited (HPPL) is a Private Limited Indian Non-Government Company incorporated in India on 25 January 2019 (Six years 14 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Taiyebi Mohammed, Salman Taiyebi, Maria Taiyebi, and Two other members serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74994TG2019PTC130042
-
Company No.
130042
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
25 Jan 2019
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Hornray Pharmasea?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Salman Taiyebi
|
Director | 25-Jan-2019 | Current |
|
Mohammed Taiyebi
|
Director | 25-Jan-2019 | Current |
|
Maria Taiyebi
|
Director | 25-Jan-2019 | Current |
|
Taiyebi Mohammed
|
Director | 25-Jan-2019 | Current |
|
Taha Taiyebi
|
Director | 25-Jan-2019 | Current |
Financial Performance of Hornray Pharmasea.
Hornray Pharmasea Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16.48% decrease in profit. The company's net worth observed a substantial decline by a decrease of 118.7%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Hornray Pharmasea?
Unlock access to Hornray Pharmasea's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Lihas Hospitality Private LimitedSalman Taiyebi and Mohammed Taiyebi are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Hornray Pharmasea?
Unlock and access historical data on people associated with Hornray Pharmasea, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Hornray Pharmasea, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hornray Pharmasea's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.